Bristol-Myers Squibb has announced that it will no longer make or sell the antidepressant Serzone

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1007, 2004-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Health Canada has granted a notice of compliance for Bristol-Myers Squibb's dasatinib [Sprycel] for use in patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1582-1583, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

The protease inhibitor atazanavir [Reyataz; Bristol-Myers Squibb] has been approved in the EU

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Bristol-Myers Squibb has issued a `Dear Health Care Provider' letter advising of a change in the pregnancy category for Sustiva [efavirenz]

By  

Reactions Weekly, Vol. 1, Iss. 1056, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS

By Mateo Ma Gracia   Gutierrez Ma del Mar   Vidal Francesc   Domingo Pere  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite

The US HHS has announced that the government will no longer pay for US immigrants' chemotherapy under Medicaid

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 543, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite